OncLive TV

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), provides an update on ibrutinib for the treatment of CLL.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the changes and challenges of treating patients with melanoma.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Pierluigi Porcu, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), discusses early research in CTCL.

Eric Padron, MD, discusses the SRSF2 mutation in patients with MDS and CMML.

Mark Shapiro, MD, PhD, discusses bosutinib as treatment for patients with CML.

Timothy S. Pardee, MD, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies.

Michael A. Caligiuri, MD, CEO, The James Cancer Hospital Solove Research Institute, director, Comprehensive Cancer Center, Ohio State University, discusses the anti-KIR antibody IPH2101 in myeloma and leukemia.

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Jennifer E. Amengual, MD, assistant professor of medicine and developmental therapeutics, member, Center for Lymphoid Malignancies, Columbia University, discusses the potential of the combination of vorinostat and niacinamide as treatment for patients with diffuse large B-cell lymphoma.

Elihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, discusses a potential change to the FDA approval process as it relates to Mylotarg (gemtuzumab ozogamicin).

Leigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.

Nicholas Turner, PhD, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

Chandra P. Belani, MD, discusses CO-1686, which is currently being studied for the treatment of non-small cell lung cancer.

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

Anne McTiernan, MD, PhD, research professor of epidemiology, University of Washington, member, Fred Hutchinson Cancer Research Center, discusses the biomarkers that are associated with poor prognosis in patients with breast cancer.

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses the use of aspirin for the prevention and treatment of colorectal cancer.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing nivolumab in the treatment of renal cell carcinoma.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Vicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses resistance in patients with GIST.

Roy S. Herbst, MD, PhD, discusses the sequencing possibilities of anti-PD-1 agents in treating patients with lung cancer.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the outlook for immunotherapies in pancreatic cancer.

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the potential of immunotherapy agents as treatment for bladder cancer.